The Oncopig Model

The Oncopig Cancer Model is an inducible translational porcine model that develops clinically relevant tumors at defined locations and timepoints.

Our Research

The Oncopig Model provides an innovative translational tool for reliable and predictable testing of cancer-related diagnostics, devices and drugs, therefore bridging the gap from murine (mouse) to human testing. Research to date shows that the Oncopig Model has many potential benefits.  Prominently, we have the ability to test and fine-tune treatment approaches in pigs before moving to clinical trials, allowing for reduction of costs associated with assessment of additional variables and accurate treatment assessment.  The Oncopig Model has the ability to mimic the human disease on a molecular basis which allow us to more accurately model the relevant clinical condition.  The ability to induce tumors and comorbidities will allows us to work precisely with defined tumors influenced by similar disease backgrounds as human diseases.  By precisely generating tumors and comorbidities in the Oncopig, which accurately mirror the human condition, our clients can evaluate their cancer diagnostics, drugs, devices, and other therapies in ways otherwise unavailable.  And because our research to date has shown the Oncopig Model can effectively predict results in humans, our clients can accelerate the most promising directions to human clinical qualification.


The Oncopig Cancer Model combined with our proprietary pig-based preclinical testing services provides the benefit of reducing false positives, modeling the interactions of multiple diseases, and accelerating progress towards human clinical trials. Our patent-pending technology allows us to induce tumors in specific sites in combination with clinically relevant comorbidities. As a result, we can work with individualized models and tumors harboring custom designed genetic modifications. Our technology has the ability to not only efficiently and effectively undergo preclinical trials, but allows us to eliminate logistical and accrual barriers associated with clinical trials, such as gender, pregnancy, age, and comorbidities.